A lack of race and ethnicity data in the treatment of hereditary hemorrhagic telangiectasia: a systematic review of intravenous bevacizumab efficacy

A lack of race and ethnicity data in the treatment of hereditary hemorrhagic telangiectasia: a systematic review of intravenous bevacizumab efficacy

Abstract Background For extreme hereditary hemorrhagic telangiectasia (HHT) disease, treatments such as intravenous bevacizumab are often utilized. However, whether its efficacy is similar across diverse races and ethnicities is unclear. Methods In this systematic review, we performed a search for E...

Full description

Bibliographic Details
Main Authors: Panagis Galiatsatos, Cheri Wilson, Jaime O’Brien, Anna J. Gong, Dylan Angiolillo, James Johnson, Carlie Myers, Sara Strout, Stephen Mathai, Gina Robinson, Nicholas R. Rowan, Clifford R. Weiss
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Hereditary hemorrhagic telangiectasia
Bevacizumab
Race
Health equity
Online Access:https://doi.org/10.1186/s13023-022-02371-0

Internet

https://doi.org/10.1186/s13023-022-02371-0

Similar Items